detorubicin has been researched along with Carcinoma* in 1 studies
1 other study(ies) available for detorubicin and Carcinoma
Article | Year |
---|---|
Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
A phase II trial of detorubicin (DTR) has been conducted on 164 patinets with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of breast carcinoma patients, in 17% of head and neck carcinoma patients and of melanoma patients, and in 6% of ureri cervic carcinoma patients. DTR seems as toxic as adriamycin on bone marrow and the heart and might induce a little less alopecia. Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasms; Uterine Neoplasms | 1980 |